Sage Therapeutics Receives Notification of PDUFA Extension for Zulresso (brexanolone) Injection

6 years ago

by David Miller

1,030 Views

Written by David Miller

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 20, 2018– Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!